Dynamic Light Scattering (DLS): Peptide Analysis Guide

# Dynamic Light Scattering (DLS) for Peptide Research: Complete Guide to Hydrodynamic Radius, Polydispersity, and Aggregation Analysis (2026)

Dynamic light scattering (DLS) is one of the most widely accessible biophysical techniques for characterizing the size, size distribution, and aggregation state of peptides in solution. Unlike surface plasmon resonance or isothermal titration calorimetry, which probe binding interactions, DLS answers a different question entirely: how big is this particle, and is my peptide behaving as a single, homogeneous species or forming higher-order assemblies?

For research laboratories investigating peptide self-assembly, amyloidogenic aggregation, or basic formulation stability, DLS is often the first analytical checkpoint — a fast, non-destructive, low-sample-volume screen that flags problems before committing material to slower or more expensive techniques like NMR or circular dichroism.

This guide covers the physical principle behind DLS, how to set up and run a measurement, how to interpret the resulting hydrodynamic radius and polydispersity index (PDI), where the technique breaks down, and how it complements other tools in the peptide analytical toolkit.

The Physical Principle: Brownian Motion and Light Scattering

DLS does not measure particle size directly. It measures the rate at which particles diffuse through solution due to Brownian motion, then converts that diffusion rate into a size using the Stokes-Einstein equation.

When a laser illuminates a suspension of particles, the particles scatter light in all directions. Because the particles are constantly moving, the intensity of scattered light detected at a fixed angle fluctuates over time — small particles diffuse quickly and produce rapid intensity fluctuations, while large particles diffuse slowly and produce slower fluctuations. A photon correlator captures these fluctuations and constructs an autocorrelation function, which decays over a characteristic timescale related to the particle's translational diffusion coefficient (D).

The Stokes-Einstein equation then converts D into a hydrodynamic radius (R_h):

R_h = k_B T / (6πηD)

where k_B is the Boltzmann constant, T is absolute temperature, and η is solvent viscosity. The result is not a physical dimension you could measure with a ruler — it is the radius of a hypothetical hard sphere that would diffuse at the same rate as the actual particle, including any bound solvation shell, hydration layer, or extended conformation. Elongated or flexible peptides therefore report a larger apparent hydrodynamic radius than a compact globular species of identical molecular weight.

What DLS Actually Reports

Most commercial DLS instruments (e.g., Malvern Zetasizer, Wyatt DynaPro) fit the correlation function using the method of cumulants, which returns two key numbers:

• •Z-average size — an intensity-weighted mean hydrodynamic diameter, dominated by the largest scatterers in the sample
• •Polydispersity Index (PDI) — a dimensionless measure (0 to 1) of the width of the size distribution

Because scattering intensity scales with the sixth power of particle radius (Rayleigh scattering, valid for particles well below the laser wavelength), a small population of large aggregates can dominate the measured signal even when it represents a tiny fraction of the sample by mass or number. A solution that is 99.9% monomeric peptide with a trace of large aggregate can still report a Z-average size skewed heavily toward the aggregate population. This is arguably the single most important caveat for interpreting DLS data on peptides, and it has been characterized quantitatively: analysis of lysozyme solutions showed DLS overestimating cluster size by a factor of roughly 1.6× and underestimating cluster concentration by an order of magnitude, due to this intensity-weighting effect (Li et al., 2011).

For samples with more than one size population, the cumulants fit breaks down, and researchers instead use a regularization algorithm (commonly CONTIN or a similar multimodal fitting routine) to resolve intensity-weighted, volume-weighted, and number-weighted distributions. These three distributions can look dramatically different for the same sample — a small aggregate peak that dominates the intensity distribution may be nearly invisible in the number distribution, since it represents very few actual particles.

Instrumentation and Measurement Geometry

DLS instruments differ mainly in detection angle:

• •90° (side) detection — the traditional geometry, well suited to larger particles and dilute samples
• •Backscatter detection (173° in Malvern instruments) — reduces multiple scattering effects and stray light contamination, allowing measurements in more concentrated or turbid samples with minimal dilution
• •Multi-angle DLS — used in more advanced setups to extract additional shape information from the angular dependence of scattering

Sample volumes are small (10–100 µL disposable cuvettes are common), measurement times are typically 1–5 minutes, and the technique is non-destructive — the same sample can be re-measured over time to track aggregation kinetics.

Sample Preparation: The Most Common Source of Bad Data

Because DLS is exquisitely sensitive to large scatterers, sample preparation is the single biggest determinant of data quality:

1. Filtration or centrifugation — samples should be passed through a 0.02–0.22 µm filter (compatible with the expected peptide size) or centrifuged to remove dust particles and large debris, which scatter far more strongly than the peptide itself and will corrupt the Z-average and PDI

2. Concentration range — too dilute and the count rate (photons/second) is too low for a reliable correlation function; too concentrated and multiple scattering and particle-particle interactions distort the diffusion measurement. Most peptide DLS protocols work in the 0.1–10 mg/mL range, though this varies by instrument sensitivity

3. Buffer matching — viscosity and refractive index of the dispersant must be entered correctly into the analysis software, since both terms appear directly in the Stokes-Einstein conversion

4. Temperature equilibration — samples should equilibrate at the measurement temperature for several minutes before data collection, since even small temperature gradients introduce convective flow that corrupts the correlation function

5. Cuvette cleanliness — scratched or dusty cuvettes are a frequent, underappreciated source of spurious large-particle signal

A useful quality check before trusting any DLS result is to inspect the raw correlation function and the count rate — a clean, smoothly decaying correlogram with a stable count rate indicates a well-behaved measurement, while a noisy or multi-exponential correlogram with rising count rate over time often indicates active aggregation happening during the measurement itself.

Interpreting the Polydispersity Index (PDI)

PDI provides a rapid triage of sample homogeneity:

• •PDI < 0.1 — highly monodisperse; a single well-defined species (or extremely tight distribution)
• •PDI 0.1–0.4 — moderately polydisperse; typical for many folded peptides and small conjugates, still generally trustworthy for cumulants analysis
• •PDI > 0.4 — broadly polydisperse or multimodal; the cumulants Z-average becomes unreliable as a single number, and distribution analysis (CONTIN) should be used instead
• •PDI approaching 1.0 — often indicates an unstable, actively aggregating, or badly contaminated sample

Tracking PDI over time (minutes to days, depending on the study) is a standard way to quantify peptide aggregation propensity in formulation and stability work, without needing a specific aggregation-detecting dye.

Applications in Peptide Research

Self-Assembly and Nanostructure Formation

Peptides engineered to self-assemble into nanofibers, hydrogels, or micelles (see our guide to self-assembling peptides) are routinely screened by DLS to confirm the transition from monomer to defined nanostructure, and to estimate the resulting particle or fiber cross-sectional dimensions. Because self-assembly is often triggered by a change in pH, ionic strength, or temperature, DLS is well suited to time-course monitoring of the assembly process, since measurements are fast and non-destructive.

Amyloidogenic Aggregation Kinetics

DLS has a long history in amyloid research, where tracking the growth of oligomeric and fibrillar species over time is central to understanding aggregation pathways relevant to neurodegenerative disease research (see our articles on amyloid-beta and alpha-synuclein). A combined DLS and Thioflavin T fluorescence apparatus applied to polyglutamine peptide aggregation revealed that the very large species detected by DLS require pre-existing fibrils to form, indicating that fibril bundling is a distinct, later-stage kinetic process layered on top of initial nucleation and elongation (Streets et al., PLOS ONE).

However, DLS has known blind spots for early-stage amyloid aggregation. Because small, low-abundance oligomers are vastly outscattered by any larger species present, bulk DLS struggles to resolve the earliest oligomeric intermediates that are often the most biologically relevant toxic species. High-throughput single-molecule photobleaching approaches have been developed specifically to fill this gap, classifying oligomer stoichiometry up to 19-mers with over 80% accuracy using machine learning models — resolution that bulk DLS cannot achieve (Tahirbegi et al., 2022, Frontiers in Chemistry).

Formulation Stability and Aggregation Screening

DLS is a standard process analytical technology in biologics and peptide formulation research, used to monitor protein/peptide folding and aggregation state during manufacturing steps such as inclusion body solubilization and refolding, where it can serve as a rapid at-line check for aggregate-free product before downstream processing (process analytical technology applications). More recently, DLS has been validated as a quality control method for detecting aggregates in radiolabeled therapeutic constructs, underscoring its continued role as a first-line stability screen even as newer techniques emerge (Evaluation of DLS for radiolabeled antibody aggregates, 2024).

Limitations of DLS for Peptide Research

DLS's convenience comes with real analytical trade-offs that every peptide researcher should understand before over-interpreting a single Z-average number:

• •Intensity-weighting bias — as discussed above, DLS dramatically overrepresents large species and underrepresents small ones, making it a poor tool for precisely quantifying trace aggregate levels
• •No absolute concentration information — DLS reports size but not the molar or mass concentration of each population present in a mixed sample; this is a major limitation for kinetic modeling, since reaction rates depend on molar concentration
• •Poor resolution for small peptides at low concentration — Taylor Dispersion Analysis (TDA), an orthogonal sizing technique based on capillary flow rather than static light scattering, was shown to provide more consistent hydrodynamic radii than DLS for small peptides and proteins (including oxytocin) at very low concentrations (0.05 mg/mL), where DLS produced unreliably inflated values (Hawe et al., 2011, Pharmaceutical Research)
• •Weak sensitivity to extended, non-spherical aggregates — elongated fibrils and rod-like assemblies scatter less efficiently per unit mass than compact spherical particles of the same molecular weight, which can cause DLS-based nanoparticle tracking methods to substantially underestimate the concentration of fibrillar aggregates even while correctly capturing their size distribution (Yang et al., 2014, AIChE Journal)
• •Multiple scattering artifacts — in concentrated or turbid samples, photons scattered by one particle may be re-scattered by another before reaching the detector, distorting the correlation function unless backscatter geometry or dilution is used

DLS vs. Complementary Sizing Methods

Because DLS and NTA have complementary blind spots — DLS lacks concentration data, NTA underestimates fibril concentration due to weak scattering from extended shapes — combining the two techniques has been shown to recover meaningful concentration estimates that neither method alone can provide (Yang et al., 2014).

Practical Protocol Recommendations

1. Filter or centrifuge every sample immediately before measurement; never trust a DLS result from an unfiltered sample

2. Run at least 3 technical replicates per sample and check for consistency in both Z-average and PDI before averaging

3. Inspect the raw correlation function, not just the fitted output — a clean single-exponential decay supports confidence in the cumulants fit

4. Report intensity-, volume-, and number-weighted distributions together when a sample is polydisperse; a single Z-average number can be actively misleading for multimodal populations

5. Treat DLS as a triage and trending tool, not a precise quantitative concentration assay — confirm significant findings (e.g., a shift toward aggregation) with an orthogonal method such as SEC, AUC, or NTA

6. For kinetic aggregation studies, keep measurement temperature strictly controlled and match it to the biologically or experimentally relevant condition, since diffusion coefficients and reaction rates are both temperature-dependent

Related Analytical Methods

DLS sits alongside a broader toolkit for characterizing peptide structure, binding, and assembly state. For binding kinetics and thermodynamics, see our guides to Surface Plasmon Resonance, Isothermal Titration Calorimetry, and Microscale Thermophoresis. For structural characterization, see NMR Spectroscopy and Circular Dichroism. For mass and purity confirmation, see MALDI-TOF Mass Spectrometry and Peptide Purity Testing.

Disclaimer

This article is for educational and research purposes only. All peptides and analytical methods discussed are intended strictly for laboratory research use (RUO). Nothing in this article constitutes medical advice, and none of the peptides referenced are intended for human or animal use, diagnosis, treatment, or prevention of any disease.